Enad Global 7 AB: EG7 implements organizational realignment which is expected to reduce annual costs by SEK 32 million from Q2 2026

Enad Global 7 AB (publ) ("EG7") today announces that the Group has completed cost-saving measures within its business units, Petrol and Piranha Games. A proposal for reduced Board remuneration has als ...

Bezeq Group Publishes its 2025 ESG Report

Holon, Israel - April 13, 2026 - Bezeq The Israeli Telecommunications Corp. Ltd. (TASE: BEZQ), Israel's leading telecommunications group, which includes Pelephone, yes, and Bezeq International Tech, p ...
Finanznachrichten

Funding Circle Holdings Plc: POS-Transaction in Own Shares

Funding Circle Holdings plc (FCH) POS-Transaction in Own Shares 13-Apr-2026 / 10:02 GMT/BST =----- LEI: 2138003EK6UAINBBUS19 13 April 2026 ...

DentSpa Healthcare Group: Rising UK Dental Costs and NHS Access Crisis Drive Record Demand for Treatment in Türkiye - DentSpa Leads the Response

According to ad hoc data released by the ONS on 19 September 2025, approximately 523,000 UK residents now travel abroad annually for dental treatment - a 50.29% ...

H. Lundbeck A/S: Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting

Seven abstracts represent data across migraine, childhood-onset epilepsy and multiple system atrophy (MSA), highlighting Lundbeck's biology-driven approach to developing treatments for serious ...

Nxera Pharma's Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia

NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with NeurocrineN ...

Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...

Sitowise Group Plc: Tero Hannuksela appointed SVP at Sitowise Buildings business area and Elisa Rusama appointed Group CHRO

Sitowise Group Plc Changes in board/management/auditors 13 April 2026 at 9.30 am EEST Tero Hannuksela has been appointed Senior Vice President, Buildings business area, and a member of the Group ...

Facephi Strengthens Its International Expansion with the Opening of a Subsidiary in Canada

Facephi Strengthens Its International Expansion with the Opening of a Subsidiary in Canada The Biometric and Digital Identity sector within the Canadian financial sector is expected to maintain CAGR ...